Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:00:02 2024-05-17 pm EDT			5-day change	1st Jan Change
4.18 ^USD	+1.95%		+1.21%	-24.00%

May. 15	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	MT
Apr. 30	Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	MT

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

September 27, 2022 at 08:45 am EDT

Marker Therapeutics, Inc. announced that the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company's capital conservation measures.

Latest news about Marker Therapeutics, Inc.

Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	May. 15	MT
Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	Apr. 30	MT
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	Jan. 22	CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	CI
Top Midday Gainers	Dec. 11	MT
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	Dec. 11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	Nov. 09	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	23-09-11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $762,658	23-08-14	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Marker Therapeutics, Inc. - Special Call	23-08-09
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting	23-08-07	MT
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union	23-07-10	MT
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401	23-07-10	CI
Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer	23-07-03	CI
Correction: Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	23-06-26	MT
Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	23-06-26	MT
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration	23-06-26	CI
Cell Ready, LLC completed the acquisition of Certain Cell Manufacturing Assets of Marker Therapeutics, Inc.	23-06-25	CI
Marker Therapeutics Says First Patient Dosed in Phase 1 Trial of Lymphoma Treatment	23-06-12	MT
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31	MT

Chart Marker Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.1 USD

Average target price

11 USD

Spread / Average Target

+168.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MARKER THERAPEUTICS, INC.	-24.00%	36.55M
MODERNA, INC.	+32.76%	50.85B
IQVIA HOLDINGS INC.	+0.17%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.99%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-22.06%	19.13B
BIO-TECHNE CORPORATION	+8.15%	13.05B
MEDPACE HOLDINGS, INC.	+27.57%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.63%	12.08B

Other Biotechnology & Medical Research